LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference�
Go back to LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference�| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 197.74 -5.42 (2.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $203.16 | 52 Week High | $333.65 | |||
| Open | $203.70 | 52 Week Low | $223.02 | |||
| Day High | $204.31 | P/E | 25.32 | |||
| Day Low | $197.40 | EPS | $7.81 | |||
| Volume | 841,352 | |||||
